Journals / Bakırköy Tıp Dergisi / 2007 / Cilt: 3 - Sayı: 3

Vertikal diplopi ile prezente olan nonptotik oküler myasteni gravis: Olgu sunumu

Non-ptotic oculer myasthenia gravis presenting with vertical diplopia: Case report

Pages
118–120
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We present a 67 year-old patient who applied to our clinic with the chief complaint of vertical diplopia

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Myasthenia Gravis is an autoimmune disease characterized by muscle strength loss due to dysfunction at the neuromuscular junction.
📊
Key Findings & Data:While ocular symptom and signs are present in up to half of the myasthenia gravis patients, only 15% of the patients’ prognosis is dominated by sole ocular symptoms.
💡
Conclusion & Impact:We present a 67 year-old patient who applied to our clinic with the chief complaint of vertical diplopia
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Yaşlı · Blefaropitoz · Çift görme

Abstract

Myasthenia Gravis is an autoimmune disease characterized by muscle strength loss due to dysfunction at the neuromuscular junction. The disease process most often begins at the adolescence and early adulthood. If the disease involves only ocular muscles, the term ocular myasthenia is used. While ocular symptom and signs are present in up to half of the myasthenia gravis patients, only 15% of the patients’ prognosis is dominated by sole ocular symptoms. The classic triad of the disease includes ptosis, diplopia and weakness of the ocular muscles. Ptosis accompanies the clinical picture in 90% of the cases but only rarely does the disease stay with ptosis as the only clinical symptom. Two- thirds of the ocular myasthenia gravis cases transform into generalized myasthenia and one-third remain as ocular myasthenia. We present a 67 year-old patient who applied to our clinic with the chief complaint of vertical diplopia

Özet

Myasteni gravis iskelet kaslarında nöromuskuler bileşkedeki disfonksiyon sonucu güç kaybıyla karakterize, otoimmun komponenti de olan bir hastalıktır. Sıklıkla adolesan ve genç erişkinlik döneminde başlar. Myasteni gravis okulomotor kasları tutarsa oküler myasteni olarak adlandırılır. Myasteni gravis hastalarının yaklaşık yarısında okuler semptom ve bulgular mevcutken, %15’i sadece oküler myasteni kliniği ile seyrederler. Ptozis, diplopi ve orbikularis okuli kasında zayışık klasik triadını oluşturur. Olguların %90’ında ptozis eşlik etmekte olup, nadiren sadece ptozisle uzun dönem seyreder. Oküler Myasteni gravis (OMG)’lilerin 2/3’ü jeneralize myasteniye dönüşürken, 1/3’ü oküler myasteni olarak kalır. Vertikal diplopi ile kliniğimize başvuran nonptotik 67 yaşında bir oküler myasteni olgusu sunduk.

🔖

Cite This Article

CİNEMRE, H., BİLİR, C., GÖKOSMANOĞLU, F., ALÇELİK, A., KORKMAZ, U., DİNDAR, G. (2007). Vertikal diplopi ile prezente olan nonptotik oküler myasteni gravis: Olgu sunumu. Bakırköy Tıp Dergisi, Cilt: 3 - Sayı: 3, 118–120. https://ajindex.com/articles/131544

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Simpson JF, Westerberg MR, Magee KR. Myasthenia gravis. An analysis of 295 cases. Acta Neurol Scand 1966; 23: 1-27
  2. Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 2004; 217: 131-133
  3. Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P. Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord 2001; 11: 208-216
  4. Huang CS, Hsu HS, Huang BS, Lee HC, Kao KP, Hsu WH, Huang MH. Factors influencing the outcome of transsternal thymectomy for myasthenia gravis. Acta Neurol Scand 2005; 112: 108-114
  5. Bever CT Jr, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol 1983; 14: 516-519
  6. Hommel M, Bogousslavsky J. The spectrum of vertical gaze palsy following unilateral brainstem stroke. Neurology 1991; 41: 1229-1234 7. Osher RH, Glaser JS. Myasthenic sustained gaze fatigue. Am J Ophthalmol 1980; 89: 443-445
  7. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987; 505: 472-499
  8. Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 2003; 23: 251–255
  9. Papapetropoulos TH, Ellul J, Tsibri E. Development of generalized myasthenia gravis in patients with ocular myasthenia gravis. Arch Neurol. 2003; 60: 1491–1492.